Alzinova
2.54 SEK -3.05%Be the first to follow this company
Alzinova is a biotechnology company. The company specializes in the therapeutic treatment of Alzheimer's and conducts research and development of peptides that are further developed as vaccines. In addition, the company also develops various research tools in the work area. The largest operations are in the Nordic market. The company was founded in 2011 and is headquartered in Gothenburg.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
ALZ
Daily low / high price
2.16 / 2.62
SEK
Market cap
226.48M SEK
Turnover
3.6M SEK
Volume
1.5M
Financial calendar
Interim report
22.08.2024
Interim report
14.11.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Maida Vale Capital | 15.2 % | 15.2 % |
Försäkrings AB Avanza Pension | 7.0 % | 7.0 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
All patients have been included and received the first dose in the high-dose cohort of the phase 1b study
Alzinova allocates shares to underwriters in connection with the completed rights issue
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools